Valeritas Holdings Inc

Valeritas — Investor Presentation (June 2018)

30 slides from Valeritas's investor presentation, Jun 4, 2018

  1. Slide 1: Valeritas Corporate Presentation May 2018

    Valeritas Corporate Presentation NASDAQ: VLRX May 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valerita

  3. Slide 3: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing  Company and its  Global Type 2 diabetes  New high-touch sa

  4. Slide 4: Type 2 Diabetes Overview: V-Go $1.6B U.S. Opportunity

    Type 2 Diabetes Overview: V-Go® $1.6B U.S. Opportunity U.S. Diabetes Market Overview1 Key Type 2 Market Data Points ~23 million diagnosed people with diabetes . 5.6 million U.S. Type 2 patients on insulin 2 ~7 million (90%-95% Type 2) Insulin Users . 80% of Type 2 patients on insulin are not achievi

  5. Slide 5: Current Insulin Delivery Standard of Care Highly Dissatisfying

    Current Insulin Delivery Standard of Care for Type 2 Highly Dissatisfying Type 2 Insulin Users Intentionally Skip and/or Current Insulin Delivery Standard of Care Forget to Take Injections1 Most Type 2 patients will not inject away from home2 “Drugs don’t work in people who don’t take them.” -C. Eve

  6. Slide 6: The V-Go Solution Designed for Patients with Type 2 Diabetes

    The V-Go® Solution Designed for Patients with Type 2 Diabetes V-Go’s Benefits Discreet, Low Profile Simple to Use Convenient Cost Neutral Better A1c Control* Self-contained Sharps Container Pharmacy vs. DME * Company data, kff.org (11 published clinical papers and 48 presentations at National Confer

  7. Slide 7: V-Go Competition: Pens not Pumps

    V-Go® Competition: Pens not Pumps Unique Needs of Type 2 Patients Creates Valeritas’ Opportunity & Differentiates it from Others TYPE 1 TYPE 2 Typical Patient Engaged / Advocate Embarrassment / Stigma Attitude Complex Device More Likely Less Likely Acceptable? (~30% of Type 1 are on pump therapy)1 W

  8. Slide 8: Strong Clinical Evidence

    Strong Clinical Evidence Demonstrated Statistically Published Significant Improvements in A1c1-10 12 Clinical Papers V-Go Patients Improved Quality of Life1 >1K Studied Lowered Total Daily Dose of Insulin Presentations at National (Prescribed / Administered)1-10 52 Conferences Demonstrated Cost Redu

  9. Slide 9: V-Go: Improved A1c Control with Less Insulin

    V-Go®: Improved A1c Control with Less Insulin A Prospective Study of 415 Patients Showed V-Go Superiority vs. Standard Treatment Optimization (STO)1 Greater Improvement in A1c2 Less Insulin Used & More Cost Effective V-Go STO n=169 n=246 29% Less Insulin with V-Go vs STO at 4 months (54 vs 72 u/day)

  10. Slide 10: New High-Touch Sales and Marketing Model

    New High-Touch Sales and Marketing Model DIRECT SALES REPs ON-LINE ADs EDUCATION PROMOTION INDIRECT REPs DEMO KIT KOLs DESIRE PRESCRIBE TARGETED PRINT ADs PATIENT PHYSICIAN CONFERENCES • Activate patients to seek and ask for V-Go® • Target high insulin volume prescribers • Direct-to-Patient multi-ch

  11. Slide 11: U.S. Direct Sales Footprint

    U.S. Direct Sales Footprint Significant Opportunity for Sustained Robust Growth via Disciplined Sales Force Expansion . ~50 Direct Reps . Disciplined addition of reps over time to achieve national coverage ©2018 Valeritas, Inc. 11

  12. Slide 12: Accelerating 20%+ Revenue Growth

    Accelerating 20%+ Revenue Growth $6,500 Sequential Quarterly Revenue Key Observations (in 000’s) (Q1 2016-Q1 2018) . Q1 ‘16 revamped sales & marketing model $6,000 • Direct reps reduced from 64 to 28 in Jan ‘16 • Focused high-touch and higher-service $5,500 sales & marketing model adopted . Q2 ‘17 i

  13. Slide 13: Our Goal: 15% Share in Addressable U.S. Markets

    13 Our Goal: 15% Share in Addressable U.S. Markets 15% Share of Type 2 Patients in U.S. (Already on Insulin but not at Goal) can Generate ~$1.6B Revenue Addressable U.S. Type 2 Target Share Annual U.S. Revenue Patient Population 2M Multiple 1 Daily Injections $700M With 15% Market Share 4.5M Insulin

  14. Slide 14: International Markets – Significant Market Opportunity

    International Markets – Significant Market Opportunity Global Diabetes Stats1 International Distribution Agreements . Currently 425 million suffer diabetes; expected to be . Recent international distribution 629 million by 2045 (~90% Type 2) agreements signed with premier regional distributors . May

  15. Slide 15: Robust Pipeline of New V-Go Products

    Robust Pipeline of New V-Go Products V-Go Line Extension Products Provide Path to the Broader Diabetes & Insulin Market V-Go® V-Go® SIMTM V-Go® Prefill1 2 • Current product (Simple Insulin Management) Expected to: • Filled by patient by transferring insulin Expected to: • Eliminate filling step as i

  16. Slide 16: Strategy for Sustained Growth & Expansion

    Strategy for Sustained Growth & Expansion + Grow Our Share Expand Our Reach Leverage Pipeline • Expand # of targets per rep • V-Go accessory • ~50 direct sales reps TM • Expand U.S. field presence V-Go® SIM with blue tooth • Targeting ~1,200 prescribers (accounts) connectivity • Drive V-Go® share in

  17. Slide 17: Stronger Device Margin Mitigates Future Capital Needed to Break-Even

    Stronger Device Margin Mitigates Future Capital Needed to Break-Even Quarterly Revenue Level at Which 45% Gross Valeritas Projected Gross Margins * $70 ($ in million) Margin was Achieved 50% GM in Q4 2018 at $60 $61.1 $7M to $8M Revenue $50 $40 . High margin at low revenue $30 . $27.0 Profitability

  18. Slide 18: Financial Summary

    Financial Summary Financial Summary Quarterly Summary Full Year Summary ($ in millions) 1Q18 1Q17 Change 2017 2016 Change Revenue $6.1 $4.6 +32% $20.2 $19.6 +3.6% Gross Profit $2.9 $1.7 +67.2% $8.2 $6.9 +17.6% Gross Margin 47.6% 37.6% +1000 bp 40.3% 35.5% +480 bp Net Loss $12.1 $11.9 +2.3% $49.3 $46

  19. Slide 19: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing  Company and its  Global Type 2 diabetes  New high-touch sa

  20. Slide 20: Valeritas Appendix May 2018

    Valeritas Corporate Presentation Appendix NASDAQ: VLRX May 2018 ©2018 Valeritas, Inc.. 20

  21. Slide 21: 4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal

    4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal Despite Serious Health Consequences % of Type 2 Patients on Insulin NOT at Goal1 Impact of Improving A1c Control2 Every 1% improvement in A1c decreases diabetes related events in: AT A1c Goal NOT AT A1c Goal 20% 80% Deaths Heart Attacks

  22. Slide 22: Significant Market Opportunity for Valeritas in the U.S.

    Significant Market Opportunity for Valeritas in the U.S. U.S. Type 2 Diabetes Initial V-Go® Target Market V-Go® Potential Revenue 5.6M Patients with Type 2 2M Type 2 on Multiple Daily Injections Diabetes On Insulin1 With Current Sales Force 15% “IF” Market Share V-G0® Revenue 2 2M on 15% $75 Million

  23. Slide 23: Robust Clinical Data Validated Ability of V-Go

    Robust Clinical Data Validated Ability of V-Go® to Deliver Clinically Relevant Reductions in A1c with Less Insulin V-GoAL1 SIMPLE2 VALIDATE 13 EVIDENT4 IMPROVE5 JONES6 KAISER7 UMASS8 MOTIV9 ENABLE10 Baseline 9.9% 8.8% 9.6% 9.7% 9.8% 9.1% 9.8% 10.7% 8.7% 9.2% N=169 N=87 N=204 N=84 N= 103 N=69 N=60 N=

  24. Slide 24: Simple Titration Approach Significantly Lowered A1c

    Simple Titration Approach Significantly Lowered A1c Use of a weekly physician-driven mealtime dosing titration approach with patients with Type 2 Diabetes uncontrolled on prior regimens A1c (%) Insulin Dose (Units) 8.7 144 A1c Goal Achievement Before V-Go® On V-Go < 7% 13% 47% 7.1* < 8% 60* 40% 87%

  25. Slide 25: Less Insulin Needed and Lower A1c vs. Multiple Injections

    Less Insulin Needed and Lower A1c vs. Multiple Injections Switching from Multiple Daily Injections to V-Go® Results in Significant Reductions in Insulin and A1c VALIDATE evaluated patients switched to V-Go when Glycemic Control was Suboptimal on Prior Regimens Prescribed On V-Go 117 Patient 102 Repo

  26. Slide 26: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle

    Patients Who Utilize V-Go® Like How it Fits into Their Lifestyle >90% of Patients are satisfied with the ability of V-Go to fit with their Lifestyle Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6% N=720 patients prescribed V-Go dLife Survey 1Q 201

  27. Slide 27: Scalable Business Model to Drive Shareholder Value

    Scalable Business Model to Drive Shareholder Value Launch V-Go® Prefill Expand Product Advance Sales Force Launch V-Go Next in U.S. V-Go SIMTM Gen / Line Collaborate (Int’l) Extensions Launch with h-Patch Expand V-Go® SIMTM Technology Increase Sales Force (U.S.) Begin to Share in U.S. prudently in C

  28. Slide 28: V-Go with V-Go SIM Technology (Simple Insulin Management)

    V-Go® with V-Go® SIM™ Technology (Simple Insulin Management)* The Future of Type 2 Diabetes Management CLOUD HOSTING Partner MANAGEMENT APPLICATIONS PATIENT PHYSICIAN INDUSTRY PAYERS V-Go SIM sends data one-way to V-Go SIM will enable simple and Adherence, utilization and other Evidence of treatment

  29. Slide 29: V-Go: Easy to Use & High Quality Commercial Scale Manufacturing

    V-Go®: Easy to Use & High Quality Commercial Scale Manufacturing V-Go Device Overview V-Go® EZ FILL Basal rate is 24 hour Basal rate begins spring-driven with the push of a button Basal Chamber Basal rate Fluid flow Piston restrictor Insulin Needle Fluid Bolus Chamber • Simple filling does not requi

  30. Slide 30: Experienced and Proven Executive Management Team

    Experienced and Proven Executive Management Team Geoffrey Jenkins EVP Manufacturing Joseph Saldanha Operations, R&D Chief Business Officer John Timberlake President & CEO, Board Member Matt Nguyen ErickLucera Chief Commercial Officer Chief Financial Officer ©2018 Valeritas, Inc. 30

Valeritas Holdings — Investor Presentation (June 2018) on 6ix